Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.68 |
| ▸ | NPC1 | O15118 | 4/20 | 0.68 |
| ▸ | RAB9A | P51151 | 3/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL794423 | 1.00 | MEN1 (0.69) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL4710641 | 1.00 | MEN1 (0.69) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL29927440 | 0.98 | MEN1 (0.68) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| Hydrochloric Acid SCHEMBL27499702 | 0.98 | MEN1 (0.68) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL7424105 | 0.98 | MEN1 (0.71) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL1000788 | 0.98 | MEN1 (0.71) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| Hydrochloric Acid SCHEMBL27804056 | 0.97 | MEN1 (0.69) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| Hydrogen Sulfide SCHEMBL28243160 | 0.97 | MEN1 (0.69) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| Methylene Chloride SCHEMBL28167523 | 0.95 | MEN1 (0.64) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL5109854 | 0.95 | MEN1 (0.71) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12103928-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2024-10-01 | — | — | US | disclosed |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-10-19 | — | — | US | disclosed |
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-08-22 | — | — | US | disclosed |
| US-11352609-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | CODEXIS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210371419-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-12-02 | — | — | US | disclosed |
| US-11117896-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-09-14 | — | — | US | disclosed |
| EP-3798214-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2021-03-31 | — | — | EP | disclosed |
| US-20200399616-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2020-12-24 | — | — | US | disclosed |
| EP-3203840-B1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2020-08-05 | — | — | EP | disclosed |
| US-20200048253-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2020-02-13 | — | — | US | disclosed |
| US-20160024090-A1 | BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-01-28 | — | — | US | disclosed |
| US-9181250-B2 | Beta-lactamase inhibitor and process for preparing the same | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-11-10 | — | — | US | disclosed |
| US-20150141401-A1 | NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857401-A1 | NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME | Meiji Seika Pharma Co., Ltd. (JP) | 2015-04-08 | — | — | EP | disclosed |
| CN-103987707-A | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | HOFFMANN LA ROCHE | 2014-08-13 | — | — | CN | disclosed |
| CN-103442568-A | Furo [3,2-d ] pyrimidine compounds | ABBVIE INC | 2013-12-11 | — | — | CN | disclosed |
| WO-2008039420-A2 | NOVEL INHIBITORS OF BETA-LACTAMASE | MERCK & CO., INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| WO-2007053495-A2 | COMPOUNDS USEFUL AS ANTAGONISTS OF CCR2 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| EP-1436255-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | Aventis Pharmaceuticals, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003024924-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | MEN1 252/4885KMT2A 4162/4885NPSR1 1054/4885 |
| US-20200048253-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | MEN1 252/4885KMT2A 4162/4885NPSR1 1054/4885 |
| US-20160024090-A1 | BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | ME1, MRPL21, FNTB | MEN1 1370/4885KMT2A 2242/4885NPSR1 3565/4885 |
| US-20150141401-A1 | NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | ME1, FN1, FNTB | MEN1 1708/4885KMT2A 2671/4885NPSR1 3433/4885 |
| US-20210371419-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | MEN1 252/4885KMT2A 4162/4885NPSR1 1054/4885 |
| US-11352609-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | AKR1C4, AKR7A2, AKR1C2 | MEN1 2203/4885KMT2A 1015/4885NPSR1 1868/4885 |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | MEN1 252/4885KMT2A 4162/4885NPSR1 1054/4885 |
| US-20200399616-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | AKR1C4, AKR7A2, AKR1C2 | MEN1 2203/4885KMT2A 1015/4885NPSR1 1868/4885 |
| US-12103928-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | MEN1 252/4885KMT2A 4162/4885NPSR1 1054/4885 |
| US-11117896-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | MEN1 252/4885KMT2A 4162/4885NPSR1 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.